Genome Med:具有超声异常和疑似孟德尔病症的胎儿的临床外显子组测序研究

2018-10-06 MedSci MedSci原创

目前外显子组测序已纳入儿科和成人人群的临床护理中,但其在产前诊断中的整合受到更多限制。其中一个原因是缺乏有关产前环境中外显子组测序的临床应用的信息。 本研究中,我们回顾了2012年3月至2017年11月期间在临床诊断实验室中进行的146个连续“胎儿外显子组”的适应症,结果,结果时间(周转时间,TAT)以及外显子组结果的影响。将胎儿外显组定义为一个对从胎儿或受孕产品获得的样品,通过产前成像或尸

目前外显子组测序已纳入儿科和成人人群的临床护理中,但其在产前诊断中的整合受到更多限制。其中一个原因是缺乏有关产前环境中外显子组测序的临床应用的信息。

本研究中,我们回顾了2012年3月至2017年11月期间在临床诊断实验室中进行的146个连续“胎儿外显子组”的适应症,结果,结果时间(周转时间,TAT)以及外显子组结果的影响。将胎儿外显组定义为一个对从胎儿或受孕产品获得的样品,通过产前成像或尸检检测到至少一个结构异常。使用Fisher精确检验进行统计学比较。

结果显示,产前外显子组产生的总分子诊断率为32%(n = 46/146)。在46个分子诊断中,50%是常染色体显性疾病(n = 23/46),41%是常染色体隐性遗传疾病(n = 19/46),9%是X连锁疾病(n = 4/46)。对于具有影响多器官系统异常的胎儿和具有颅面畸形的胎儿,分子诊断率最高。在146例患者中,对62例胎儿标本进行了为正在进行的妊娠设计的产前三重外显子组件选项,诊断产率为35%,初始报告的平均TAT为14天(不包括组织培养时间)。分子诊断可精确的评估复发风险,改变医疗管理和家庭的知情生殖计划。

总之,该研究表明,当胎儿结构异常表明遗传病因学时,外显子组测序是一种有用的诊断工具,但其他标准的产前基因检测未提供诊断。

原始出处:

Elizabeth A. Normand, Alicia Braxton, et al., Clinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder. Genome Med. 2018; 10: 74.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689721, encodeId=27341689e212e, content=<a href='/topic/show?id=4bf4428668c' target=_blank style='color:#2F92EE;'>#外显子组测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42866, encryptionId=4bf4428668c, topicName=外显子组测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c628851013, createdName=dlwang_26703136, createdTime=Sat Mar 02 11:38:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684252, encodeId=a4b216842521e, content=<a href='/topic/show?id=a2a842865e7' target=_blank style='color:#2F92EE;'>#外显子组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42865, encryptionId=a2a842865e7, topicName=外显子组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5dc28064977, createdName=achengzhao, createdTime=Tue Nov 06 02:38:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609155, encodeId=cdc9160915566, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619047, encodeId=cb35161904ea2, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689721, encodeId=27341689e212e, content=<a href='/topic/show?id=4bf4428668c' target=_blank style='color:#2F92EE;'>#外显子组测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42866, encryptionId=4bf4428668c, topicName=外显子组测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c628851013, createdName=dlwang_26703136, createdTime=Sat Mar 02 11:38:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684252, encodeId=a4b216842521e, content=<a href='/topic/show?id=a2a842865e7' target=_blank style='color:#2F92EE;'>#外显子组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42865, encryptionId=a2a842865e7, topicName=外显子组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5dc28064977, createdName=achengzhao, createdTime=Tue Nov 06 02:38:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609155, encodeId=cdc9160915566, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619047, encodeId=cb35161904ea2, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689721, encodeId=27341689e212e, content=<a href='/topic/show?id=4bf4428668c' target=_blank style='color:#2F92EE;'>#外显子组测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42866, encryptionId=4bf4428668c, topicName=外显子组测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c628851013, createdName=dlwang_26703136, createdTime=Sat Mar 02 11:38:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684252, encodeId=a4b216842521e, content=<a href='/topic/show?id=a2a842865e7' target=_blank style='color:#2F92EE;'>#外显子组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42865, encryptionId=a2a842865e7, topicName=外显子组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5dc28064977, createdName=achengzhao, createdTime=Tue Nov 06 02:38:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609155, encodeId=cdc9160915566, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619047, encodeId=cb35161904ea2, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1689721, encodeId=27341689e212e, content=<a href='/topic/show?id=4bf4428668c' target=_blank style='color:#2F92EE;'>#外显子组测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42866, encryptionId=4bf4428668c, topicName=外显子组测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c628851013, createdName=dlwang_26703136, createdTime=Sat Mar 02 11:38:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684252, encodeId=a4b216842521e, content=<a href='/topic/show?id=a2a842865e7' target=_blank style='color:#2F92EE;'>#外显子组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42865, encryptionId=a2a842865e7, topicName=外显子组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5dc28064977, createdName=achengzhao, createdTime=Tue Nov 06 02:38:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609155, encodeId=cdc9160915566, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619047, encodeId=cb35161904ea2, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Oct 08 06:38:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]